In a race to overcome the ravages of the coronavirus co·ro·na·vi·rus : any of a family (Coronaviridae) of single-stranded RNA viruses that have a lipid envelope studded with club-shaped projections, infect birds and many mammals including humans, and include the causative agents of MERS, SARS, and COVID-19, the FDA has approved emergency protocols allowing doctors to treat critically ill COVID-19 \ ˈkō-vid-nīn-ˈtēn : a mild to severe respiratory illness that is caused by a coronavirus (Severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus), is transmitted chiefly by contact with infectious material (such as respiratory droplets), and is characterized especially by fever, cough, and shortness of breath and may progress to pneumonia and respiratory failure. patients with plasma from survivors in the hope that the treatment will be effective in dulling the effects of COVID-19. The experimental treatment, reserved for patients who are in dire condition and at risk of death, is being instituted on a case-by-case basis until more sophisticated therapies and an eventual vaccine can be developed.
The treatment involves harvesting anti-body rich plasma donated by coronavirus survivors to treat patients who are critically ill with the virus vi·rus | \ ˈvī-rəs : a disease-causing agent that is too tiny to be seen by the ordinary microscope, that may be a living organism or may be a very special kind of protein molecule, and that can only multiply when inside the cell of an organism under the new emergency protocols approved Tuesday. This method, called convalescent-plasma therapy Convalescent plasma is the liquid part of blood that is collected from patients who have recovered from an infection. Antibodies present in convalescent plasma are proteins that might help fight the infection. Convalescent plasma is being investigated for the treatment of COVID-19 because there is no approved treatment for this disease and there is some information that suggests it might help some patients recover from COVID-19. Further investigation is still necessary to determine if convalescent plasma might shorten the duration of illness,reduce morbidity, or pre..., dates back to the late 19th century and was previously used during the 2002 SARS särz : a severe respiratory illness that is caused by a coronavirus (species Severe acute respiratory syndrome-related virus of the genus Betacoronavirus), is transmitted especially by contact with infectious material (such as respiratory droplets or body fluids), and is characterized by fever, headache, body aches, a dry cough, hypoxia, and usually pneumonia — called also severe acute respiratory syndrome outbreak out·break | \ ˈau̇t-ˌbrāk : a sudden, rapid rise in the incidence of a disease and the flu pandemic (pan·dem·ic) : an outbreak of a disease that occurs over a wide geographic area and affects an exceptionally high proportion of the population : a pandemic outbreak of a disease. of 1918. The CDC encourages donating blood if you are well.
“Although promising, convalescent plasma has not been shown to be effective in every disease studied,” the FDA announcement said. “It is therefore important to determine through clinical trials, before routinely administering convalescent plasma to patients with COVID-19, that it is safe and effective to do so.”
The highly infectious virus has topped 600,000 cases worldwide, and it continues to take a massive toll on the healthcare system due to the severe nature of the symptoms. Approximately 20% of cases require hospitalization, and the most stricken patients must be placed on a ventilator ven·ti·la·tor | \ ˈven-tə-ˌlā-tər : a machine that provides mechanical ventilation by moving breathable air into and out of the lungs, to deliver breaths to a patient who is physically unable to breathe, or breathing insufficiently..
Two hospitals in New York City, Mount Sinai and Albert Einstein College of Medicine, hope to start using coronavirus-survivor plasma as early as next week to treat people with the disease.
“Every patient that we can keep out of the ICU is a huge logistical victory because there are traffic jams in hospitals,” said Michael Joyner, an anesthesiologist and physiologist at the Mayo Clinic in Rochester, Minnesota.
If a loved one is sick with COVID-19, your household will need to take extra precautions to keep from spreading the virus.
U.S. research trials also are expected to commence soon. The New York Blood Center plans to send out plasma for clinical trials at several hospitals, such as Johns Hopkins, the Mayo Clinic, and Montefiore Medical Center. The Johns Hopkins trial will enroll people who have been exposed to COVID-19 but who do not yet have symptoms, while Mayo and Monefiore will focus on people early into their illness.
Researchers plan to infuse patients at an early stage of the disease to see how often they advance to critical care. Another would explore plasma’s use as a preventative measure for people in close contact with those confirmed to have COVID-19 and evaluate how often such people fall ill after an infusion compared with others who were similarly exposed but not treated.
These outcomes are measurable within a month, said Liise-anne Pirofski, an infectious-disease specialist at Albert Einstein College of Medicine. “Efficacy data could be obtained very, very quickly.”
This virus is to be taken seriously. Please follow every precaution to protect yourself and others from passing on this highly infectious virus.